Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which they are receiving single agent or combination immunotherapy or within the last 6 months.
Rheumatologist-established diagnosis of new onset CTCAE grade 2-3 immunotherapy-induced inflammatory arthritis or activated osteoarthritis, involving one or more joints (up to 3) including but not limited to hands, shoulders, elbows, hips, knees and ankles.
Age ≥ 40 years.
ECOG performance status ≤2 (Karnofsky ≥60%).
Patients with ability and willingness to sign consent.
You may not be if
Contraindications to radiation treatment, such as pregnancy, breast-feeding women and active collagen-vascular disease.
Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \>1 year prior to consent and/or clear documentation states that the patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment.
Have not received systemic steroids within the last 3 months for the treatment of immune related adverse events.
History of prior autoimmune conditions, or concurrent immune related adverse events requiring systemic immunosuppressants.
Estimated life expectancy less than 3 months as assessed by investigators.
Any condition at the discretion of investigator that will preclude participation in the study.
History of secondary malignancy as assessed by investigators.
History of radiation to affected joints as assessed by investigators.
Clareo Health | Radiation to Treat Joint Damage Caused by Cancer Immunotherapy
